Osborn onboard at Onyx as SVP
This article was originally published in Scrip
Onyx Pharmaceuticals has appointed John Osborn senior vice-president of global corporate affairs following the departure of Laura Brege, formerly the company's executive vice-president of corporate affairs, who has joined Delcath Systems' board of directors. Mr Osborn will report to Dr Anthony Coles, president and CEO. Prior to joining Onyx, he was executive vice-president, general counsel and secretary at Dendreon Corporation.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.